Oxford BioMedica (OXB); signs partnership to develop gene therapy for cystic fibrosis

Published on 06-08-2018 07:07:07
Author Sparks Team

OXB has entered into collaboration with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations to develop a long-term therapy for patients with cystic fibrosis (CF).

The approach being taken by the partnership has demonstrated high gene transfer efficiency, offers the possibility of repeated administration to maintain a therapeutic effect and has the potential to address more than 2,000 different, known gene mutations across patients. OMB will be work in processes and analytical development, scaling up manufacturing and generating data for toxicity studies.

Separately, OMB has granted Boehringer Ingelheim an option to license exclusive global rights for the former’s lentiviral vector technology.

Share this with friends and colleagues

Company list